Prostate Cancer
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
January 9, 2024
Tissue contamination challenges the credibility of machine learning models in real world digital pathology.
January 9, 2024
Adverse events and costs among non-metastatic castration-resistant prostate cancer patients.
January 8, 2024
Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer.
January 8, 2024
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.
January 8, 2024
Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.
January 8, 2024
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker.
January 8, 2024
Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells - implications for systemic control.
January 8, 2024
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
January 5, 2024
Approach to Patients with High-Risk Localized Prostate Cancer: Radiation Oncology Perspective.
January 5, 2024